T regulatory cells in B-cell malignancy - tumour support or kiss of death?

Immunology

Volumn 135, Issue 4, 2012, Pages 255-260

  Lindqvist, Camilla A ^a   Loskog, Angelica S I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

B cell leukaemia; B cell lymphoma; Cytotoxic regulatory cells; Immune regulation; T regulatory cells

Indexed keywords

TUMOR MARKER;

AUTOIMMUNITY; B CELL LEUKEMIA; CANCER MORTALITY; CANCER STAGING; CYTOTOXIC LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

B-LYMPHOCYTES; CELL DIFFERENTIATION; HUMANS; LEUKEMIA, B-CELL; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; T-LYMPHOCYTES, REGULATORY;

EID: 84857753221     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03539.x     Document Type: Review

References (106)

1. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49:1603-16.
2. Oble DA, Loewe R, Yu P, Mihm MC Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immunol 2009; 9:3.
3. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
4. + regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13:902-11.
5. Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling E. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cylooxygenase-2-positive uveal melanoma. Cancer 2010; 116:2224-33.
6. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS, Niedobitek G. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkins lymphoma. Hematol Oncol 2009; 27:31-9.
7. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11:1467-73.
8. Carreras J, Lopez-Guillermo A, Fox BC et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108:2957-64.
9. Lee NR, Song EK, Jang KY et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008; 49:247-56.
10. + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93:193-200.
11. Wahlin BE, Aggarwal M, Montes-Moreno S et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16:637-50.
12. Koreishi AF, Saenz AJ, Persky DO, Cui H, Moskowitz A, Moskowitz CH, Teruya-Feldstein J. The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2010; 18:206-11.
13. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128:958-65.
14. Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970; 18:723-37.
15. Gershon RK, Kondo K. Infectious immunological tolerance. Immunology 1971; 21:903-14.
16. Basten A, Fazekas de St Groth B. Special regulatory T-cell review: T-cell dependent suppression revisited. Immunology 2008; 123:33-9.
17. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
18. high regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53.
19. + T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303-10.
20. + T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285-94.
21. + regulatory T cells. Eur J Immunol 2002; 32:1621-30.
22. + regulatory T cells. Semin Immunol 2004; 16:89-98.
23. Mays LE, Chen YH. Maintaining immunological tolerance with Foxp3. Cell Res 2007; 17:904-18.
24. Fransson M, Burman J, Lindqvist C, Atterby C, Fagius J, Loskog A. T regulatory cells lacking CD25 are increased in MS during relapse. Autoimmunity 2010; 43:590-7.
25. - subpopulations. J Immunol 2000; 165:3105-10.
26. + T cells in patients with systemic lupus erythematosus. J Immunol 2009; 182:1689-95.
27. + regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302.
28. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303-10.
29. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16:311-23.
30. + regulatory T cells that are expanded at tumor sites. J Immunol 2010; 184:6545-51.
31. + regulatory T cells. Int Immunol 2004; 16:1643-56.
32. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
33. + regulatory T cells. Nat Immunol 2003; 4:330-6.
34. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007; 445:936-40.
35. + T reg cells. J Exp Med 2006; 203:1701-11.
36. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci 2005; 102:5138-43.
37. Zhou Z, Song X, Berezov A, Li B, Greene MI. Structural aspects of the FOXP3 regulatory complex as an immunopharmacological target. Int Immunopharmacol 2009; 9:518-20.
38. Zhou Z, Song X, Li B, Greene MI. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol Res 2008; 42:19-28.
39. + regulatory T cells. Trends Immunol 2006; 27:541-4.
40. + T cells. Eur J Immunol 2007; 37:129-38.
41. + FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983-90.
42. - effector T cells. Int Immunol 2008; 20:421-31.
43. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345-54.
44. Pillai V, Karandikar NJ. Attack on the clones? Human FOXP3 detection by PCH101, 236A/E7, 206D, and 259D reveals 259D as the outlier with lower sensitivity. Blood 2008; 111:463-4.
45. + regulatory T cells. Mol Immunol 2010; 47:1595-600.
46. + T regulatory cells. J Immunol 2010; 184:3433-41.
47. Bettini ML, Vignali DA. Development of thymically derived natural regulatory T cells. Ann N Y Acad Sci 2010; 1183:1-12.
48. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.
49. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204:1765-74.
50. + follicular regulatory T cells control the germinal center response. Nat Med 2011; 17:975-82.
51. Chung Y, Tanaka S, Chu F et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 2011; 17:983-8.
52. Alexander CM, Tygrett LT, Boyden AW, Wolniak KL, Legge KL, Waldschmidt TJ. T regulatory cells participate in the control of germinal centre reactions. Immunology 2011; 133:452-68.
53. + regulatory T cells. Nat Rev Immunol 2011; 11:119-29.
54. - T cells of are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007; 178:6725-9.
55. Zhou X, Bailey-Bucktrout SL, Jeker LT et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000-7.
56. Shalev I, Schmelzle M, Robson SC, Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol 2011; 23:282-92.
57. + anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99:2468-76.
58. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159:4772-80.
59. Willems F, Marchant A, Delville JP, Gerard C, Delvaux A, Velu T, de Boer M, Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24:1007-9.
60. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
61. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24:99-146.
62. Collison LW, Workman CJ, Kuo TT et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450:566-9.
63. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37:3021-9.
64. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65.
65. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 2006; 177:6780-6.
66. Bopp T, Becker C, Klein M et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007; 204:1303-10.
67. Novak TJ, Rothenberg EV. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci USA 1990; 87:9353-7.
68. + adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 2006; 177:246-54.
69. Goto T, Herberman RB, Maluish A, Strong DM. Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 1983; 130:1350-5.
70. Lindqvist CA, Christiansson LH, Simonsson B, Enblad G, Olsson-Stromberg U, Loskog AS. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010; 131:371-6.
71. Angelini G, Gardella S, Ardy M et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci 2002; 99:1491-6.
72. Fallarino F, Grohmann U, Hwang KW et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4:1206-12.
73. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002; 9:1069-77.
74. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev 2007; 7:817-23.
75. + responder cells by Fas-mediated apoptosis. J Immunol 2009; 182:1469-80.
76. + T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003; 171:4604-12.
77. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004; 104:2840-8.
78. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21:589-601.
79. Mahnke K, Bedke T, Enk AH. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 2007; 250:1-13.
80. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635-46.
81. + T cells selectively kill B lymphocytes. Blood 2006; 107:3925-32.
82. + T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010; 32:266-78.
83. + regulatory T cells. Cell Death Differ 2007; 14:2076-84.
84. + T cells. Blood 2007; 109:2058-65.
85. Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007; 56:1687-700.
86. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp (Warsz) 2006; 54:323-33.
87. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-cell lymphoma in different risk groups defined by the international prognostic index. Arch Immunol Ther Exp (Warsz) 2010; 58:131-41.
88. + T cells to T-regulatory cells. Int J Cancer 2009; 124:239-44.
89. Choe J, Kim HS, Zhang X, Armitage RJ, Choi YS. Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. J Immunol 1996; 157:1006-16.
90. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5:251-62.
91. Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P., Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011; 96:408-16.
92. Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest 2004; 114:1640-9.
93. + follicular helper T cells. J Immunol 2008; 181:6038-50.
94. - T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology 2011; 133:296-306.
95. Iikuni N, Lourenco EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol 2009; 183:1518-22.
96. Caligaris-Cappio F. Inflammation, the microenvironment and chronic lymphocytic leukemia. Haematologica 2011; 96:353-5.
97. Catera R, Silverman GJ, Hatzi K et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008; 14:665-74.
98. Lanemo Myhrinder A, Hellqvist E, Sidorova E et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111:3838-48.
99. Borche I, Liam A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990; 76:562.
100. Sthoeger ZM, Wakai M, Tse DB. Production of autoantibodies by CD5-expressing B lymphocytes in patients with chronic lymphocytic leukemia. J Exp Med 1989; 169:255-68.
101. Ansell P, Simpson J, Lightfoot T et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter? Int J Cancer 2011; 129:460-6.
102. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-85.
103. + regulatory T cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103:3428-30.
104. + T cells in the thymus of patients with myasthenia gravis. Blood 2005; 105:735-41.
105. hi T-regulatory cells. Blood 2006; 108:253-61.
106. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-88.